[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preserved-ejection-fraction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preserved-ejection-fraction":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,77,107,141,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":41,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100636568","cartiz-registry-cartilage-arthropathy-and-imaging-under-tirzepatide-in-zone-stratified-cohorts---a-four-institute-mexican-observational-registry-100636568",false,"NCT07567378","CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry","Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts (CARTIZ): A Prospective Observational Multi-Institutional Registry of the VAT-Articular-Cardiac-Aging Axis in Adults Exposed to Tirzepatide in Mexico, With Quantitative Knee Cartilage T2 Mapping, Cardiac CT Epicardial Adipose Tissue Radiomic Phenotyping, HLA Stratification, Longitudinal Multi-Frequency Bioimpedance Body Composition, and a Prespecified Surgical Tissue Acquisition Subcohort","CARTIZ","Inclusion Criteria:\n\n* 1\\. Age ≥18 years at the time of informed consent. 2. Currently receiving tirzepatide under an independent clinical indication (type 2 diabetes, insulin resistance, obesity with or without associated metabolic disease, renal protection, metabolic hypertension, or associated off-label metabolic use) prescribed by the treating physician independently of the registry.\n\n  3\\. Presence of at least one objectively documented musculoskeletal manifestation - current or historical - defined as any of: (i) inflammatory arthralgia affecting one or more joints with clinical, imaging, or serological support; (ii) CASPAR-positive psoriatic arthritis; (iii) radiographically documented knee osteoarthritis; (iv) enthesitis on physical examination or ultrasound; (v) documented inflammatory arthropathy of the spine or peripheral joints with a specialist diagnosis.\n\n  4\\. For the retrospective-prospective component: availability of clinical documentation of articular state prior to tirzepatide initiation in the patient's medical record. Documentation may include physical examination notes, imaging, laboratory values, or specialist consultation notes.\n\n  5\\. Signed informed consent for registry enrolment, longitudinal serum biobanking, HLA typing at INCMNSZ, quantitative knee MRI with T2 mapping at Ci3M UAM-Iztapalapa at Week 0 and Week 52, non-contrast cardiac CT at INCar at Week 0 and Week 52, multi-frequency bioelectrical impedance analysis at Universidad La Salle México at six timepoints, and (where applicable) medical record review. Each attestation is consented modularly within a single document.\n\n  6\\. Clinical plan to continue tirzepatide for at least 52 weeks from registry Week 0, based on the treating physician's evaluation of current clinical indication. Discontinuation during follow-up is captured as an outcome variable and does not remove the patient from the registry.\n\n  7\\. Capacity to attend scheduled follow-up visits and to undergo bilateral knee MRI at Ci3M (without severe claustrophobia requiring sedation, without absolute contraindication to MRI - see Exclusion 6) and non-contrast cardiac CT at INCar (without uncontrolled arrhythmia precluding ECG-gated imaging of diagnostic quality).\n\nFor the Surgical Tissue Subcohort (Cohort 3) only - additional criteria applied at the time of subcohort enrolment:\n\n8s. Scheduled clinically indicated cardiac surgery at the Instituto Nacional de Cardiología Ignacio Chávez (coronary artery bypass grafting, valve replacement, or combined procedures) during registry follow-up.\n\n9s. Specific additional informed consent for intraoperative collection of epicardial adipose tissue fragments.\n\nExclusion Criteria:\n\n* 1\\. Initiation or modification of a biologic disease-modifying antirheumatic drug (biologic DMARD) or JAK inhibitor within the 12 weeks prior to Week 0, or clinically anticipated initiation or modification during the first 12 weeks of follow-up. Washout may permit re-screening.\n\n  2\\. Major joint surgery within the 3 months prior to Week 0, or planned major joint surgery within the 12 months following Week 0, involving any joint scheduled for evaluation in the registry.\n\n  3\\. Intra-articular corticosteroid or hyaluronic acid injection within the 6 weeks prior to baseline biospecimen collection in any joint. Patients beyond the 6-week washout are eligible.\n\n  4\\. Active malignancy, with the exception of adequately treated non-melanoma skin carcinoma. History of malignancy in remission ≥5 years is permitted at the discretion of the treating investigator.\n\n  5\\. Current pregnancy, lactation, or planned pregnancy within the 12-month observation period.\n\n  6\\. Absolute contraindication to MRI, including non-MRI-compatible cardiac pacemaker or implanted defibrillator, ferromagnetic intracranial vascular clips, non-documented non-MRI-compatible cochlear implants, or other contraindication per the local MRI safety protocol.\n\n  7\\. Systemic rheumatologic disease other than psoriatic arthritis or osteoarthritis requiring active immunomodulation, specifically: seropositive rheumatoid arthritis on biologic therapy, active systemic lupus erythematosus on immunomodulation, active vasculitis on immunosuppression, or other systemic disease whose treatment confounds the inflammatory axis the registry is designed to characterize.\n\n  8\\. Inability to provide informed consent (cognitive impairment, language barrier not resolvable with site interpreter, or other incapacity to understand the protocol), or anticipated inability to complete the 52-week follow-up.\n\nFor the Surgical Tissue Subcohort (Cohort 3) only - additional exclusions:\n\n9s. Prior major cardiac surgery resulting in extensive pericardial adhesions that preclude safe intraoperative EAT fragment collection, as assessed by the operating cardiac surgeon.\n\n10s. Emergency cardiac surgery precluding the specific informed consent process.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","52 Weeks","OBSERVATIONAL","CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1\u002FGIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance, obesity, renal protection, metabolic hypertension, or associated off-label metabolic use. The registry is entirely observational: CARTIZ does not initiate, modify, interrupt, or supply tirzepatide, and does not dictate dose, route, or duration. All pharmacological exposure decisions are made by the treating physician independently of study participation. The registry is operationalized through a four-institute architecture integrating three Mexican National Institutes of Health and one national imaging laboratory. Core 1 (Knee Cartilage Imaging, Ci3M UAM-Iztapalapa) performs bilateral 3T MRI with quantitative T2 mapping at Week 0 and Week 52. Core 2 (Cardiac Imaging, Instituto Nacional de Cardiología Ignacio Chávez) performs non-contrast cardiac computed tomography for radiomic phenotyping of epicardial adipose tissue at Week 0 and Week 52 under cardiovascular Co-Principal Investigator Dr. Erick Alexánderson Rosas. Core 3 (HLA Typing, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Transplant Department) performs Class I and Class II HLA typing by PCR-SSO Reverse Luminex. Core 4 (Body Composition, Universidad La Salle México) performs multi-frequency bioelectrical impedance analysis (seca mBCA) at six longitudinal timepoints capturing visceral adipose tissue trajectory, phase-angle trajectory, appendicular skeletal muscle mass, and hydration ratios at zero marginal cost. The registry enrolls n=30 patients across three clinical sites with identical protocol (IMSS Clínica Río Magdalena, INCMNSZ outpatient clinic, and a private practice site in Mexico City), generating 60 evaluable knees and 30 paired cardiac CT studies. The primary co-endpoints address a mechanistic question no other tirzepatide study is positioned to answer: whether the articular response to tirzepatide in inflammatory arthropathy precedes and mechanistically precedes weight loss, through formal mediation analysis of Week-4 ACR20 response via high-sensitivity C-reactive protein, SERPINB2, and dipeptidyl peptidase-4 activity, restricted to the Mechanistic Analysis Set of patients with tirzepatide exposure ≤16 weeks at Week 0 and delta-BMI \\\u003C1.0 kg\u002Fm² through Week 4. A prespecified Surgical Tissue Subcohort is declared at initial registration to establish public scientific priority on direct human epicardial adipose tissue transcriptomic characterization under dual GIP\u002FGLP-1 receptor agonism. Subcohort participants who undergo clinically indicated cardiac surgery at INCar during follow-up (coronary artery bypass grafting, valve replacement, or combined procedures) are invited to provide specific additional informed consent for collection of epicardial adipose tissue fragments routinely excised during operative access and otherwise discarded as surgical waste. Operational launch is contingent on separate INCar tissue-specific approvals and will proceed via PRS record amendment when ready",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Psoriatic Arthritis","Osteoarthitis","Knee","Diabetes (DM)","Type 2 Diabetes Mellitus (T2DM)","Obesity (Disorder)","Insulin Resistance Syndrome","Metabolic Syndrome","Heart Failure","Preserved Ejection Fraction","Coronary Artery Disease","Atrial Fibrillation (AF)","Non Alcholic Fatty Liver Disease","Sarcopenia","Pericardium",[42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63],"Tirzepatide","Dual GIP\u002FGLP-1 receptor agonist","Multi-nutrient-stimulated hormones","Psoriatic arthritis","Inflammatory arthropathy","ACR20","Cartilage T2 mapping","Quantitative knee MRI","Epicardial adipose tissue","Cardiac CT radiomics","Fat Attenuation Index","HLA typing","Visceral adipose tissue","Phase angle","seca mBCA","Bioelectrical impedance analysis","Mediation analysis","Weight-independent effect","Off-label exposure","Mexican registry","Epicardial adipose transcriptomics","Single-nucleus RNA sequencing","NOT_YET_RECRUITING","2026-05-07",{"date":67,"type":68},"2026-05-12","ACTUAL",{"date":70,"type":21},"2026-05",{"date":72,"type":21},"2029-05",{"name":74,"class":75},"JULIO GRANADOS MONTIEL","OTHER",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":76},"100630918","precision-rehabilitation-for-veterans-with-hfpef-100630918","NCT07493915","Precision Rehabilitation for Veterans With (HFpEF)","Precision Rehabilitation for Veterans With Heart Failure With Preserved Ejection Fraction (HFpEF)","Inclusion Criteria:\n\n* New York Heart Association Class II or III HF symptoms\n* History of hypertension\n* EF≥50%\n* LVH confirmed by echocardiography, Cardiac CT, or Cardiac MR\n* Diastolic dysfunction which must include ≥2 of the following:\n\n  1. Average E\u002Fe'\\>14\n  2. Septal e'\\\u003C7 cm\u002Fs or Lateral e' \\\u003C10 cm\u002Fs\n  3. TR velocity\\> 2.8 m\u002Fs\n  4. LA computed volume index \\>34 mL\u002FM2\n  5. PCWP or LVEDP\\>15\n* Ability to participate in an exercise program as determined by a research, cardiology, or primary care provider\n\nExclusion Criteria:\n\n* Ejection Fraction \\\u003C 50%\n* Absence of LVH\n* LV Dilation (LV end diastolic volume indexed to BSA \\> 75 ml\u002Fm2)\n* Any Segmental wall motion abnormality\n* Acute ST segment elevation myocardial infarction (STEMI)\n* Significant valvular or other non-coronary heart disease\n* Any non-cardiac disease or condition that could influence myocardial function (e.g., collagen-vascular disease, history of cardiotoxic cancer chemotherapy, amyloid)\n* Anemia defined as Hgb \\\u003C 11.0 g\u002Fdl in males, 10 g\u002Fdl in females\n* Current accelerating angina, unstable angina, angina at rest, or NSTEMI within 3 months\n* Chronic pulmonary disease requiring home oxygen or steroid therapy\n* Significant non-CV organ disease: Chronic hepatic or renal disease (eGFR \\\u003C 25 mL\u002Fmin\u002F1.73m2)\n* Inability to provide informed consent\n* Inability to perform exercise",{"count":85,"type":21},4,"This study is being completed because there is conflicting information regarding the value of monitored exercise in patients with heart failure with preserved ejection fraction (HFpEF). The purpose of this study is to collect baseline information necessary for researchers to pursue a larger study evaluating how monitored exercise performed during cardiac rehabilitation may improve heart health and the amount of oxygen delivered to the tissues during exercise. Researchers must first examine whether the facility is capable of supporting such a study and whether in a modest number of patients, there is no clear detrimental effect to exercise. Rather, there may be an important improvement that has been underestimated to date.\n\nParticipation will require a time commitment for performing exercise 3 times per week for 12 weeks in addition to having a small amount of blood drawn twice. There will also be a specialized form of a stress test (cardiopulmonary exercise test; \"CPET\") with ultrasound imaging of the heart (echocardiography) completed twice.",[34,35],[89,90,91,92,93,94,95],"heart failure","preserved ejection fraction","cardiac rehab","CPET","rehabilitation","HFpEF","veterans","RECRUITING","2026-03-20",{"date":99,"type":68},"2026-03-25",{"date":101,"type":68},"2023-06-01",{"date":103,"type":21},"2026-10-09",{"name":105,"class":106},"Columbia VA Health Care System","FED",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":76},"100612203","left-bundle-branch-pacing-vs-right-ventricular-pacing-on-ahre-burden-in-patients-with-preserved-lvef-100612203","NCT07250529","Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF","Comparison of Left Bundle Branch Pacing Versus Conventional Right Ventricular Pacing on AHRE Burden in Patients With Preserved Left Ventricular Ejection Fraction and High Ventricular Pacing Dependency (LBBP-AHRE Trial): A Randomized Study","LBBP-AHRE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Scheduled implantation of a dual-chamber pacemaker for:\n\nPermanent complete heart block Permanent second-degree AV block (Mobitz II or Mobitz I)\n\n* Documented preserved LVEF (≥50%)\n* Sinus rhythm at baseline\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* History of paroxysmal, persistent, or permanent atrial fibrillation\n* Previous atrial fibrillation ablation (catheter-based or surgical)\n* LVEF \\\u003C 50%\n* Sinus node disease\n* Transient AV block requiring pacemaker implantation\n* Significant structural or valvular heart disease\n* Requirement for pacemaker system upgrade during the study period\n* Requirement for antiarrhythmic therapy for causes other than atrial fibrillation\n* Existing pacemaker or other cardiac device requiring modification for study participation\n* Enrollment in another clinical trial that could interfere with study endpoints or pacing parameters\n* Contraindication to LBBP or associated lead implantation procedure\n* Life expectancy \\\u003C 12 months\n* Any condition judged by the investigator to compromise participation or the integrity of study data",{"count":116,"type":21},244,"INTERVENTIONAL",[119],"NA","This prospective, randomized controlled trial aims to evaluate the effect of left bundle branch pacing (LBBP) compared with conventional right ventricular (RV) pacing on the cumulative duration (total time) of atrial high-rate episodes (AHREs) in patients with preserved left ventricular ejection fraction (LVEF) who are expected to require frequent ventricular pacing.\n\nAtrial High-Rate Episodes (AHREs) are defined as episodes of atrial tachyarrhythmia that are automatically recorded by device diagnostics and detected by implanted cardiac devices. These episodes usually have an atrial rate ≥170 beats per minute and a duration ≥6 minutes. AHREs are linked to a higher risk of thromboembolic events and clinical atrial fibrillation (AF), and they may indicate subclinical AF or other atrial tachyarrhythmias.\n\nChronic RV pacing has been linked to mechanical and electrical dyssynchrony, which may encourage atrial remodeling and the development of AF. LBBP provides a more physiological ventricular activation and may reduce atrial tachyarrhythmia time (AHRE time).\n\nPatients with LVEF \\>50% and atrioventricular (AV) conduction disorders requiring a dual-chamber pacemaker will be randomized to either conventional RV septal pacing or LBBP.",[37,122,123,35],"Pacemaker Therapy","Atrioventricular Block",[125,126,127,128,129,34,130,131],"Left bundle branch pacing","Cardiac electrophysiology","Right ventricular pacing","AHRE burden","Preserved ejection fraction","Quality of life","Pacing-induced cardiomyopathy (PICM)","2026-03-10",{"date":134,"type":68},"2026-03-13",{"date":136,"type":68},"2026-02-05",{"date":138,"type":21},"2029-06-20",{"name":140,"class":75},"University Hospital of Patras",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":4},"100596595","real-world-study-to-describe-the-effectiveness-and-safety-outcomes-of-jardiance-in-chinese-patients-with-heart-failure-and-preserved-ejection-fraction-100596595","NCT07047508","Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction","A Non-interventional Study of the Effectiveness and Safety Outcomes in Patients With Heart Failure and Preserved Ejection Fraction (HFpEF) Initiating Jardiance in China: A Sub-study of the Post-marketing Study of Jardiance Among Patients With Heart Failure in China","Inclusion criteria:\n\n* At least 18 years of age\n* At least 6 months of data prior to the index date\n* Left ventricular ejection fraction (LVEF) \\> 40 %\n* N-terminal Pro-B-type natriuretic peptide (NT-proBNP) \\> 125 pg\u002FmL or brain natriuretic peptide (BNP) ≥ 35 pg\u002FmL\n* At least 1 diagnosis of Heart failure with preserved ejection fraction (HFpEF) or Heart failure with mid-range ejection fraction (HFmrEF) or chronic heart failure (CHF) at baseline during the look-back period (on or prior to the index date)\n* New users of Jardiance® (initiating Jardiance® on or after March 1st, 2023, and without any record of Jardiance® prescription during the look-back period)\n* Body Mass Index (BMI) \\\u003C45 kg\u002Fm2\n\nExclusion criteria:\n\n-Patients treated with any other sodium-glucose cotransporter-2 inhibitors (SGLT2i) on the index date or during the look-back period",{"count":149,"type":21},3000,"The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.",[34,35],"2026-02-12",{"date":154,"type":68},"2026-02-13",{"date":156,"type":21},"2028-01-31",{"date":158,"type":21},"2028-12-31",{"name":160,"class":161},"Boehringer Ingelheim","INDUSTRY",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":117,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":76},"100446781","chronic-heart-failure-with-preserved-ejection-fraction---congestion-evaluation-100446781","NCT05097898","Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation","Évaluation de la Congestion en Ambulatoire Chez Les Patients Atteints d'Insuffisance Cardiaque Chronique à Fraction d'éjection préservée. CHF-COV Preserved (Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation)","CHF-COV-P","Inclusion Criteria:\n\n* Patients with chronic acute heart failure with preserved ejection fraction admitted in hospital for scheduled day hospitalization or consultation\n* Patient with preserved left ventricular ejection fraction (≥50%).\n* Age ≥18 years\n* Patients having received complete information regarding the study design and having signed their informed consent form.\n* Patient affiliated to or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Comorbidity for which the life expectancy is ≤ 3 months\n* Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate \\\u003C15 ml\u002Fmin\u002Fm2 at inclusion.\n* History of lobectomy or pneumonectomy lung surgery\n* Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.\n* Pregnant woman, parturient or nursing mother\n* Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n* Adult person who is unable to give consent\n* Person deprived of liberty by a judicial or administrative decision,\n* Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.",{"count":171,"type":21},200,[119],"Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality \u002F integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation.\n\nThe main objective of the CHF-COV Preserved study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF with preserved left ventricular ejection fraction that are associated with the risk of all-cause death, hospitalization for acute HF or IV diuretics injection in a day hospital.",[175,35],"Chronic Heart Failure","2023-06-02",{"date":178,"type":68},"2023-06-05",{"date":180,"type":68},"2022-08-10",{"date":182,"type":21},"2029-06-10",{"name":184,"class":75},"Central Hospital, Nancy, France"]